NEW YORK – Helaina, a New York-based biotechnology company producing breast milk proteins, has launched effera. Effera is a human lactoferrin equivalent ingredient.
Helaina’s precision fermentation process may replicate an equivalent protein to the lactoferrin found in human colostrum and maternal milk, according to the company.
The company said it ran a clinical study that was a randomized, double-blind controlled study to measure the body’s responses to its effera product.
Helaina said it found participants taking bovine lactoferrin produced antibodies against the protein, suggesting an immunogenic response against bovine lactoferrin. It also found participants taking effera, at both a high and low dose, produced no antibodies against the protein, suggesting better tolerability of the ingredient, according to the company.
“We are starting to see with real clinical evidence and science-backed research that human proteins can outperform bovine milk protein, opening a new world where our nutrients can do more for us,” said Laura Katz, founder and chief executive officer of Helaina. “This exciting new discovery fosters our goal of developing a portfolio of advanced human bioactive proteins that address real health needs and new possibilities in nutrition science.”
In July 2023, Helaina won IFT FIRST’s pitch event taking home the $10,000 grand prize for its human lactoferrin product. The human lactoferrin product is a bioactive compound that “regulates iron levels, improves nutrient absorption and improves cognitive health,” said Paola Delgado, chief operating officer.Enjoying this content? Learn about more disruptive startups on the Food Entrepreneur page.
